Table 3 Clinical features of gene mutations in AML (class II mutations)
From: Current findings for recurring mutations in acute myeloid leukemia
Gene | Clinical Features | Selected Ref. | Frequency |
|---|---|---|---|
Runx1 | In multivariable analysis, RUNX1 mutations were an independent prognostic marker for shorter EFS. Independent unfavorable prognosis for OS for RUNX1 mutation. | 5.6% in AML 13.2% in de novo non-M3AML 32.7% in CN or noncomplex karyotype AML | |
C/EBPα | C/EBPα mutations had a trend for a better CR rate and significantly greater 5-year rates of EFS, DFS and OS. | 5-14% in AML | |
MLL rearr. | Patients with MLL rearrangement had a lower EFS and a higher probability of relapse than MLL wild type patients. | [81] | 4-14% in AML |